TY - JOUR
T1 - Predictive factors of surgical complications after pelvic exenteration for gynecological malignancies: a large single-institution experience
AU - Tortorella, Lucia
AU - Marco, Cintoni
AU - Loverro, Matteo
AU - Carmine, Conte
AU - Persichetti, Eleonora
AU - Bizzarri, Nicolò
AU - Barbara, Costantini
AU - Francesco, Santullo
AU - Foschi, Nazario
AU - Gallotta, Valerio
AU - Avesani, Giacomo
AU - Chiantera, Vito
AU - Ercoli, Alfredo
AU - Fanfani, Francesco
AU - Fagotti, Anna
AU - Mele, Maria Cristina
AU - Restaino, Stefano
AU - Gueli Alletti, Salvatore
AU - Scambia, Giovanni
AU - Vizzielli, Giuseppe
PY - 2024
Y1 - 2024
N2 - Objective: To evaluate pre-operative predictors of early (<30 days) severe complications (grade Dindo 3+) in patients with gynecological malignancy submitted to pelvic exenteration (PE). Methods: We retrospectively analyzed 129 patients submitted to surgery at Fondazione Policlinico Gemelli between 2010 and 2019. We included patients affected by primary or recurrent/persistent cervical, endometrial, or vulvar/vaginal cancers. Post-operative complications were graded according to the Dindo classification. Logistic regression was used to analyze potential predictors of complications. Results: We performed 63 anterior PE, 10 posterior PE, and 56 total PE. The incidence of early severe post-operative complications was 27.9% (n=36), and the early mortality rate was 2.3% (n=3). More frequent complications were related to the urinary diversion and intestinal surgery. In univariable analysis, hemoglobin <= 10 g/dL (odds ratio [OR]=4.2; 95% confidence interval [CI]=1.65-10.7; p=0.003), low albumin levels (OR=3.9; 95% CI=1.27-12.11; p=0.025), diabetes (OR=4.15; 95% CI=1.22-14.1; p=0.022), 2+ comorbidities at presentation (OR=5.18; 95% CI=1.49-17.93; p=0.012) were predictors of early severe complications. In multivariable analysis, only low hemoglobin and comorbidities at presentation were independent predictors of complications. Conclusion: Pelvic exenteration is an aggressive surgery characterized by a high rate of post-operative complications. Pre-operative assessment of comorbidities and patient health status are crucial to better select the right candidate for this type of surgery.
AB - Objective: To evaluate pre-operative predictors of early (<30 days) severe complications (grade Dindo 3+) in patients with gynecological malignancy submitted to pelvic exenteration (PE). Methods: We retrospectively analyzed 129 patients submitted to surgery at Fondazione Policlinico Gemelli between 2010 and 2019. We included patients affected by primary or recurrent/persistent cervical, endometrial, or vulvar/vaginal cancers. Post-operative complications were graded according to the Dindo classification. Logistic regression was used to analyze potential predictors of complications. Results: We performed 63 anterior PE, 10 posterior PE, and 56 total PE. The incidence of early severe post-operative complications was 27.9% (n=36), and the early mortality rate was 2.3% (n=3). More frequent complications were related to the urinary diversion and intestinal surgery. In univariable analysis, hemoglobin <= 10 g/dL (odds ratio [OR]=4.2; 95% confidence interval [CI]=1.65-10.7; p=0.003), low albumin levels (OR=3.9; 95% CI=1.27-12.11; p=0.025), diabetes (OR=4.15; 95% CI=1.22-14.1; p=0.022), 2+ comorbidities at presentation (OR=5.18; 95% CI=1.49-17.93; p=0.012) were predictors of early severe complications. In multivariable analysis, only low hemoglobin and comorbidities at presentation were independent predictors of complications. Conclusion: Pelvic exenteration is an aggressive surgery characterized by a high rate of post-operative complications. Pre-operative assessment of comorbidities and patient health status are crucial to better select the right candidate for this type of surgery.
KW - Cervical Cancer
KW - Endometrial Cancer
KW - Nutritional Status
KW - Pelvic Exenteration
KW - Cervical Cancer
KW - Endometrial Cancer
KW - Nutritional Status
KW - Pelvic Exenteration
UR - https://publicatt.unicatt.it/handle/10807/283479
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85178888210&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85178888210&origin=inward
U2 - 10.3802/jgo.2024.35.e4
DO - 10.3802/jgo.2024.35.e4
M3 - Article
SN - 2005-0380
VL - 35
SP - 1
EP - 15
JO - Journal of Gynecologic Oncology
JF - Journal of Gynecologic Oncology
IS - 1
ER -